NO932983L - Fettsyrebehandling - Google Patents

Fettsyrebehandling

Info

Publication number: NO932983L
Authority: NO; Norway
Prior art keywords: fatty acid; acid treatment; treatment; dgla; efa
Prior art date: 1992-08-21

Application number

NO932983A

Other languages

English (en)

Other versions

NO932983D0 (no

NO306655B1 (no

Inventor

David Frederick Horrobin

Brenda Elizabeth Reynolds

Original Assignee

Scotia Holdings Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-21

Filing date

1993-08-20

Publication date

1994-02-22

1993-08-20 Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc

1993-08-20 Publication of NO932983D0 publication Critical patent/NO932983D0/no

1994-02-22 Publication of NO932983L publication Critical patent/NO932983L/no

1999-12-06 Publication of NO306655B1 publication Critical patent/NO306655B1/no

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fats And Perfumes (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Fertilizers (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO932983A 1992-08-21 1993-08-20 Anvendelse av GLA, DGLA eller LA ved fremstilling av et medisinsk preparat NO306655B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB929217780A GB9217780D0 (en)	1992-08-21	1992-08-21	Fatty acid treatment

Publications (3)

Publication Number	Publication Date
NO932983D0 NO932983D0 (no)	1993-08-20
NO932983L true NO932983L (no)	1994-02-22
NO306655B1 NO306655B1 (no)	1999-12-06

Family

ID=10720716

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO932983A NO306655B1 (no)	1992-08-21	1993-08-20	Anvendelse av GLA, DGLA eller LA ved fremstilling av et medisinsk preparat

Country Status (21)

Country	Link
US (1)	US5618558A (no)
EP (1)	EP0585026B1 (no)
JP (1)	JPH06157303A (no)
KR (1)	KR940003553A (no)
CN (1)	CN1049334C (no)
AT (1)	ATE159856T1 (no)
AU (1)	AU666747B2 (no)
CA (1)	CA2104567A1 (no)
DE (1)	DE69315020T2 (no)
DK (1)	DK0585026T3 (no)
ES (1)	ES2110060T3 (no)
GB (1)	GB9217780D0 (no)
GR (1)	GR3025898T3 (no)
HK (1)	HK1000997A1 (no)
MY (1)	MY109928A (no)
NO (1)	NO306655B1 (no)
NZ (1)	NZ248422A (no)
RU (1)	RU2122409C1 (no)
SG (1)	SG80536A1 (no)
TW (1)	TW323230B (no)
ZA (1)	ZA935976B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9325445D0 (en)	1993-12-13	1994-02-16	Cortecs Ltd	Pharmaceutical formulations
GB9403855D0 (en) *	1994-03-01	1994-04-20	Scotia Holdings Plc	Fatty acid derivatives
EP0711503A3 (en) *	1994-11-14	1997-11-26	Scotia Holdings Plc	Milk fortified with GLA and/or DGLA
US5804210A (en) *	1996-08-07	1998-09-08	Wisconsin Alumni Research Foundation	Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
GB9617847D0 (en)	1996-08-27	1996-10-09	Scotia Holdings Plc	Fatty acid treatment
WO1999003456A2 (en) *	1997-07-16	1999-01-28	Societe Des Produits Nestle S.A.	Method for prophylaxis or treatment of bone density loss
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6479545B1 (en) *	1999-09-30	2002-11-12	Drugtech Corporation	Formulation for menopausal women
EG22407A (en) *	2000-02-17	2003-01-29	Iams Company	Method for improving bone modeling and chondrocyte functioning in growing canines
EP1370257B1 (en) *	2001-03-15	2007-07-25	DSM IP Assets B.V.	COMPOSITION FOR THE PREVENTION OF OSTEOPOROSIS consisting of A COMBINATION OF ISOFLAVONES AND POLYUNSATURATED FATTY ACIDS
CA2442692A1 (en) *	2001-03-30	2002-10-10	The Nisshin Oillio, Ltd.	Bone metabolism improving agents
US7098352B2 (en) *	2001-11-16	2006-08-29	Virtus Nutrition Llc	Calcium salt saponification of polyunsaturated oils
WO2005063231A2 (en) *	2003-12-31	2005-07-14	Igennus Limited	Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
EA200602014A1 (ru) *	2004-04-30	2007-08-31	ВИРТУС НЬЮТРИШН ЭлЭлСи	Синтез солей одновалентных и двухвалентных металлов полиненасыщенных жирных кислот
EP1968402A2 (en) *	2005-10-07	2008-09-17	Ocean Nutrition Canada Limited	Salts of fatty acids and methods of making and using thereof
DE102007022694A1 (de) *	2007-05-11	2008-11-13	Humana Milchunion Eg	Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme
DE102007039310A1 (de) *	2007-08-13	2009-02-19	Eberhard-Karls-Universität Tübingen Universitätsklinikum	Zusammensetzung zur Prophylaxe und Behandlung von Osteoporose
US8343753B2 (en) *	2007-11-01	2013-01-01	Wake Forest University School Of Medicine	Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP3187182B1 (en)	2008-09-02	2021-03-03	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
RU2505292C2 (ru)	2009-02-10	2014-01-27	Амарин Фармасьютикалз Айрлэнд Лимитед	Способы лечения гипертриглицеридемии
MX377553B (es)	2009-04-29	2025-03-10	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
CN107233337A (zh)	2009-04-29	2017-10-10	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
GB0907413D0 (en)	2009-04-29	2009-06-10	Equateq Ltd	Novel methods
BRPI1011883A2 (pt) *	2009-06-15	2016-09-13	Amarin Pharma Inc	uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en)	2009-09-23	2014-05-30	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CA3066588C (en) *	2010-03-04	2022-03-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating and/or preventing cardiovascular disease
US8178707B2 (en)	2010-03-25	2012-05-15	Jost Chemical Company	Co-precipitated salts of fatty acids
CN101978949A (zh) *	2010-11-16	2011-02-23	王京南	γ-亚麻酸酯脂肪乳静脉注射液及其制造方法
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en)	2010-11-29	2019-10-25	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8293790B2 (en)	2011-10-19	2012-10-23	Dignity Sciences Limited	Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
WO2013070735A1 (en)	2011-11-07	2013-05-16	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
EP2800469B1 (en)	2012-01-06	2021-08-25	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
US9603826B2 (en)	2012-06-29	2017-03-28	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US8728546B1 (en)	2013-03-15	2014-05-20	Swing Aerobics Licensing, Inc.	Medicament for treatment of cancer, cardiovascular diseases and inflammation
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
MX375328B (es)	2014-06-04	2025-03-06	Ds Biopharma Ltd	Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
MX379148B (es) *	2016-06-01	2025-03-10	Soc Des Produits Nestle S A Star	Composición para usar en la profilaxis de enfermedades alérgicas.
US10966951B2 (en)	2017-05-19	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA50490A (fr)	2018-09-24	2020-09-02	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CA3160676A1 (en)	2019-11-12	2021-05-20	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
US20210315851A1 (en)	2020-04-03	2021-10-14	Afimmune Limited	Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1417119A (en) *	1972-11-30	1975-12-10	Thiele G H	Process for treating bones
GB8621816D0 (en) *	1986-09-10	1986-10-15	Efamol Ltd	Therapeutic composition
JPH0625057B2 (ja) *	1987-12-14	1994-04-06	日本油脂株式会社	骨形成促進剤
GB9112052D0 (en) *	1991-06-05	1991-07-24	Efamol Holdings	Fatty acid treatment

1992
- 1992-08-21 GB GB929217780A patent/GB9217780D0/en active Pending
1993
- 1993-08-16 AT AT93306444T patent/ATE159856T1/de not_active IP Right Cessation
- 1993-08-16 ES ES93306444T patent/ES2110060T3/es not_active Expired - Lifetime
- 1993-08-16 JP JP5202396A patent/JPH06157303A/ja active Pending
- 1993-08-16 US US08/106,989 patent/US5618558A/en not_active Expired - Fee Related
- 1993-08-16 DK DK93306444.6T patent/DK0585026T3/da active
- 1993-08-16 EP EP93306444A patent/EP0585026B1/en not_active Expired - Lifetime
- 1993-08-16 AU AU44666/93A patent/AU666747B2/en not_active Ceased
- 1993-08-16 ZA ZA935976A patent/ZA935976B/xx unknown
- 1993-08-16 SG SG9605801A patent/SG80536A1/en unknown
- 1993-08-16 DE DE69315020T patent/DE69315020T2/de not_active Expired - Fee Related
- 1993-08-17 NZ NZ248422A patent/NZ248422A/en unknown
- 1993-08-20 KR KR1019930016204A patent/KR940003553A/ko not_active Ceased
- 1993-08-20 RU RU93049153A patent/RU2122409C1/ru active
- 1993-08-20 CA CA002104567A patent/CA2104567A1/en not_active Abandoned
- 1993-08-20 NO NO932983A patent/NO306655B1/no not_active IP Right Cessation
- 1993-08-21 MY MYPI93001672A patent/MY109928A/en unknown
- 1993-08-21 CN CN93118320A patent/CN1049334C/zh not_active Expired - Fee Related
- 1993-08-23 TW TW082106797A patent/TW323230B/zh active
1997
- 1997-12-29 HK HK97102670A patent/HK1000997A1/en not_active IP Right Cessation
1998
- 1998-01-14 GR GR980400071T patent/GR3025898T3/el unknown

Also Published As

Publication number	Publication date
GR3025898T3 (en)	1998-04-30
EP0585026A1 (en)	1994-03-02
KR940003553A (ko)	1994-03-12
NO932983D0 (no)	1993-08-20
AU4466693A (en)	1994-02-24
ZA935976B (en)	1994-03-14
SG80536A1 (en)	2001-05-22
EP0585026B1 (en)	1997-11-05
AU666747B2 (en)	1996-02-22
DK0585026T3 (da)	1998-06-02
NZ248422A (en)	1997-06-24
TW323230B (no)	1997-12-21
RU2122409C1 (ru)	1998-11-27
ATE159856T1 (de)	1997-11-15
CN1091285A (zh)	1994-08-31
NO306655B1 (no)	1999-12-06
US5618558A (en)	1997-04-08
GB9217780D0 (en)	1992-10-07
ES2110060T3 (es)	1998-02-01
DE69315020D1 (de)	1997-12-11
CN1049334C (zh)	2000-02-16
JPH06157303A (ja)	1994-06-03
MY109928A (en)	1997-09-30
HK1000997A1 (en)	1998-05-15
CA2104567A1 (en)	1994-02-22
DE69315020T2 (de)	1998-04-16

Legal Events

Date	Code	Title	Description
2002-04-02	MM1K	Lapsed by not paying the annual fees	Free format text: LAPSED IN FEBRUARY 2002

Publication	Publication Date	Title
NO932983D0 (no)	1993-08-20	Fettsyrebehandling
AU562938B2 (en)	1987-06-25	7, 10, 13, 16 docosatetraenoic acid composition
RU93049153A (ru)	1996-06-10	Лечение жирными кислотами
ATE98125T1 (de)	1993-12-15	Zusammensetzungen essentieller fettsaeuren und therapie.
ES2166381T3 (es)	2002-04-16	Tratamiento de enfermedades vasculares hiperproliferativas.
GR3018157T3 (en)	1996-02-29	Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use.
DE59107331D1 (de)	1996-03-14	Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen
ES2045120T4 (es)	1996-07-16	Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.
ES2055406T3 (es)	1994-08-16	Composicion para el tratamiento de la inflamacion.
ES2107622T3 (es)	1997-12-01	Medicamento para el tratamiento de la distrofia vulvar o la sequedad vaginal.
ZA893086B (en)	1990-12-28	4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial disease
NO932984D0 (no)	1993-08-20	Fettsyrebehandling
ATE142491T1 (de)	1996-09-15	Mittel zur behandlung des atopischen ekzems und anderen entzündlichen hautkrankheiten
ATE63684T1 (de)	1991-06-15	Deodorant.
DK0520372T3 (da)	1997-05-12	Inositol-phosphat-analoger som calciumantagonistiske stoffer
ES2049703T1 (es)	1994-05-01	Derivados de acidos biliares sulfurados.
FR2716891B1 (fr)	1996-06-14	Produits colloïdaux contenant du calcium, du baryum et/ou du magnésium ainsi que du bismuth, modifiés par action d'acides carboxyliques contenant du soufre et éventuellement de l'azote.
MX9203784A (es)	1992-09-01	Composiciones para el tratamiento de osteoporosis en seres humanos.
ITFE910011V0 (it)	1991-08-06	Dispositivo antialgale battericida nella filtrazione - purificazione depurazione dell'acqua trattata localmente per uso alimentare - indus-triale - cosmesi - ecc.